Avita Medical Raises $15M in Private Placement

Avita Medical ( (RCEL) ) just unveiled an announcement.

On August 12, 2025, AVITA Medical announced the successful completion of a private placement in Australia, raising approximately US$15 million through the issuance of 17.2 million new CHESS Depositary Interests (CDIs) on the ASX. The proceeds will be used for working capital and strategic growth, with the company expecting to achieve free cash flow by 2026. This move reflects strong investor confidence in AVITA’s strategy and its acute wound care portfolio, further solidifying its market position.

The most recent analyst rating on (RCEL) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.

Spark’s Take on RCEL Stock

According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.

Avita Medical’s stock score reflects a blend of strong revenue growth and technical momentum, offset by severe profitability challenges and high financial leverage. While future revenue projections and product expansions are promising, underlying financial weaknesses and valuation concerns present significant risks.

To see Spark’s full report on RCEL stock, click here.

More about Avita Medical

AVITA Medical is a leading therapeutic acute wound care company known for delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery. Its flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds and is designed to harness a patient’s own skin to create Spray-On Skin Cells. AVITA Medical also holds exclusive rights to manufacture and distribute PermeaDerm and Cohealyx in the U.S., and its RECELL System is approved in several international markets.

Average Trading Volume: 325,875

Technical Sentiment Signal: Sell

Current Market Cap: $128M

Learn more about RCEL stock on TipRanks’ Stock Analysis page.